AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company’s cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.

阿斯利康与CSPC制药集团有限公司（CSPC）签订了独家许可协议，以推进早期新型小分子脂蛋白（a）（Lp（a））干扰物的开发，该干扰物有可能为血脂异常患者提供额外益处。这项资产进一步加强了公司的心血管投资组合，有助于解决导致慢性心血管疾病的主要风险因素。

.

.

Under the terms of the agreement, AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibitor, AZD0780..

根据协议条款，阿斯利康将获得CSPC的临床前候选小分子YS2302018，一种口服Lp（a）干扰物，目的是将其开发为一种新型降脂疗法，具有单独或联合使用一系列心血管疾病适应症的潜力，包括口服小分子PCSK9抑制剂AZD0780。。

YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a). Lp(a) is a form of low-density lipoprotein (LDL) that plays a key role in the transport of cholesterol in the blood stream.1 Elevated levels of Lp(a), as well as elevated LDL-cholesterol, are known risk factors for cardiovascular disease, including coronary artery disease and stroke.2.

YS2302018是由CSPC发现的，已被证明可以有效防止Lp（a）的形成。Lp（a）是低密度脂蛋白（LDL）的一种形式，在血液中胆固醇的运输中起着关键作用。Lp（a）水平升高以及LDL胆固醇升高是已知的心血管疾病的危险因素，包括冠状动脉疾病和中风。

Sharon Barr, Executive Vice President and Head of BioPharmceuticals R&D, AstraZeneca, said: “This asset is an important addition to our cardiovascular pipeline and could help patients to more effectively manage their dyslipidaemia and related cardiometabolic diseases. Given the scale of unmet need, with cardiovascular disease being a leading cause of death globally, advancing novel therapies that can be used alone or in combination to effectively address known risk factors and advance patient care is particularly important and a key part of our strategy.”.

阿斯利康（AstraZeneca）执行副总裁兼生物制药研发主管莎伦·巴尔（SharonBarr）表示：“这项资产是我们心血管管道的重要补充，可以帮助患者更有效地管理血脂异常和相关的心脏代谢疾病。鉴于未满足需求的规模，心血管疾病是全球死亡的主要原因，推进新的治疗方法，可以单独使用或联合使用，以有效解决已知的风险因素，推进患者护理，这一点尤为重要，也是我们战略的关键部分。”。

Dongchen Cai, Chairman of the Board, CSPC Pharmaceutical Group Ltd, said “Lipoprotein (a) represents a very important target for dyslipidemia and implicated in multiple cardiometabolic diseases. Through this agreement with AstraZeneca and their global capabilities in clinical development and commercialisation, we look forward to accelerating the development of YS2302018, a novel small molecule Lp(a) disruptor to benefit the millions of patients worldwide living with these diseases.”.

CSPC制药集团有限公司董事会主席蔡东辰表示：“脂蛋白（a）是血脂异常的一个非常重要的靶点，与多种心脏代谢疾病有关。通过与阿斯利康的协议以及他们在临床开发和商业化方面的全球能力，我们期待着加速YS2302018的开发，这是一种新型的小分子Lp（a）干扰物，使全球数百万患有这些疾病的患者受益。”。

Financial considerations

财务考虑

CSPC will receive an upfront payment of $100 million from AstraZeneca. CSPC is also eligible to receive up to $1.92 billion for further development and commercialisation milestones plus tiered royalties.

CSPC将从阿斯利康获得1亿美元的预付款。CSPC也有资格获得高达19.2亿美元的进一步开发和商业化里程碑以及分层版税。

Notes

注释

About dyslipidaemia and cardiovascular disease

关于血脂异常和心血管疾病

Elevated Lp(a) and LDL-c  levels in plasma are a key risk factor for cardiovascular disease and this is estimated to cause 2.6 million deaths worldwide annually.2,3 Despite current treatment options, the global burden of dyslipidaemia is on the rise.4 More than 70% of patients with atherosclerotic cardiovascular disease (ASCVD) are still not achieving their LDL-C target, so there remains a vast unmet need among high-risk patients for more varied and effective treatment options.5,6 AstraZeneca is investing in a pipeline of medicines for addressing risk factors and slowing progression to chronic cardiovascular disease, including AZD0780, an oral small molecule PCSK9 inhibitor under investigation for the treatment of dyslipidaemia.7.

血浆中Lp（a）和LDL-c水平升高是心血管疾病的关键危险因素，据估计每年在全球范围内导致260万人死亡。2,3尽管有目前的治疗选择，但血脂异常的全球负担正在上升。4超过70%的动脉粥样硬化性心血管疾病（ASCVD）患者仍未达到其LDL-c目标，因此高危患者对更多样化和有效治疗选择的需求仍未得到满足。5,6阿斯利康正在投资一系列药物，以解决危险因素并减缓慢性心血管疾病的进展，包括AZD0780，一种正在研究的口服小分子PCSK9抑制剂，用于治疗血脂异常。

AstraZeneca in CVRM

阿斯利康在CVRM

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies.

心血管、肾脏和代谢（CVRM）是生物制药的一部分，是阿斯利康的主要疾病领域之一，也是该公司增长的关键驱动力。阿斯利康通过遵循科学知识，更清楚地了解心脏、肾脏、肝脏和胰腺之间的潜在联系，正在通过减缓或阻止疾病进展，投资一系列器官保护药物，并最终为再生疗法铺平道路。

The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively..

该公司的目标是通过更好地了解CVRM疾病之间的相互关系并针对驱动疾病的机制来改善和挽救数百万人的生命，以便我们能够更早，更有效地检测，诊断和治疗人们。。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢以及呼吸和免疫学）处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。

Contacts

联系人

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

有关如何联系投资者关系团队的详细信息，请单击此处。有关媒体联系人，请单击此处。

References

参考文献

1. Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016;2:7. Published 2016 Mar 31. doi:10.1186/s40842-016-0024-x.

1.Saeedi R，Frohlich J.脂蛋白（a），一种独立的心血管危险标志物。临床糖尿病内分泌。2016年；2： 七。2016年3月31日发布。doi:10.1186/s40842-016-0024-x。

2. Vinci P, Di Girolamo FG, Panizon E, et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023;20(18):6721. Published 2023 Sep 6. doi:10.3390/ijerph20186721.

。国际环境公共卫生杂志。2023年；20（18）：6721。2023年9月6日发布。doi:10.3390/ijerph20186721。

3. World Health Organization (WHO) [Internet]. Raised cholesterol; [cited 2024 October 02. Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3236.

3、世界卫生组织（WHO）[互联网]。胆固醇升高；[引自2024年10月2日。可从以下地址获得：https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3236.

4. Pirillo A, et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700.

4.Pirillo A等人，《血脂异常的全球流行病学》。Nat Rev Cardiol公司。2021年；18（10）：689-700。

5. Cannon CP, et al. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6(9):1-9.

5.Cannon CP等人。在美国动脉粥样硬化性心血管疾病患者登记处GOULD使用降脂疗法超过2年。JAMA Cardiol。2021年；6（9）：1-9。

6. Krahenbuhl S, et al. Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs. 2016;76(12):1175-90.

6.Krahenbuhl S等人。降低LDL-C的未满足需求：当他汀类药物不起作用时！毒品。2016年；76（12）：1175-90。

7. Vega RB, et al. AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of  hypercholesterolemia: Results from a randomized, single-blind, placebo-controlled phase 1 trial European Atherosclerosis Society Congress; May 26-29; Lyon, France 2024.

7.Vega RB等人AZD0780，第一种用于治疗高胆固醇血症的口服小分子PCSK9抑制剂：来自欧洲动脉粥样硬化协会大会的随机，单盲，安慰剂对照1期试验的结果；5月26-29日；法国里昂，2024年。

Adrian Kemp

阿德里安·肯普

Company Secretary

公司秘书

AstraZeneca PLC

阿斯利康